Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH et al.
Published on: 3 May 2024
Article ID: rct021